Kalydeco

Chemical Nameivacaftor
Dosage FormTablets (oral; 150mg)
Drug ClassCFTR potentiators
SystemRespiratory
CompanyVertex Pharms Inc
Approval Year2012

Indication

  • For the treatment of cystic fibrosis (CF) in patients age 4 months and older who have one mutation in the CFTR gene that is responsive to ivacaftor based on clinical and/or in vitro assay data.
Last updated on 5/10/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Kalydeco (ivacaftor) Prescribing Information2012Vertex Pharmaceuticals Inc., Boston, MA